Climate-Driven Inhalers Bespak is actively developing low carbon or low GWP pressurised metered dose inhalers and has publicly pursued climate friendly inhaler initiatives. With projects like the first low carbon pMDI approved for sale and partnerships to transition to climate friendly inhalers, Bespak is well positioned to serve pharma customers prioritising sustainability and regulatory climate targets. This creates sales opportunities for development collaborations, component supply and manufacturing capacity aligned to ESG goals.

Capacity Expansion Advantage Chiesi's expansion of pMDI manufacturing capacity at Bespak's Holmes Chapel site signals strong, long term demand for Bespak's manufacturing services. Recent headcount growth also underscores the ability to scale programs from development through commercialization. This presents opportunities to secure multi year manufacturing agreements, capacity planning for large inhaler programs, and cross selling of device components and valve and actuator supply.

End-to-End CDMO Bespak offers end to end services from early feasibility and development to pilot, clinical and commercial fill finish, plus device and component manufacturing. This integrated CDMO capability reduces program risk and accelerates time to market for drug device combinations. It also enables cross selling of inhaler devices, components and high volume manufacturing of valves and actuators for pMDIs and DPIs.

Sustainability Credentials Bespak's sustainability initiatives include a biodiversity footprint assessment with Tunley Environmental, reflecting a structured ESG program. This differentiates Bespak for customers with ESG sourcing criteria and regulatory sustainability requirements. The ability to quantify and communicate supply chain impact can support winning business with climate conscious pharma groups.

Strategic Credibility Bespak's strategic partnerships with Chiesi and collaboration with Orbia, plus leadership appointments, bolster credibility and network access in the inhalation space. This can help accelerate introductions to decision makers at target pharma companies and enable faster discussions for new programs and capacity commitments.